Suspected DVT is a same-day problem. New, unexplained swelling, pain or tenderness, warmth, or redness in one leg (usually the calf or thigh) needs urgent medical evaluation – do not “wait and see,” because early treatment prevents a clot from breaking loose. Call 911 or go to the nearest emergency room immediately if you have signs of a pulmonary embolism: sudden shortness of breath, chest pain that gets worse when you breathe in, coughing up blood, a racing heartbeat, lightheadedness, or fainting. A pulmonary embolism is a life-threatening emergency. And if you are already on a blood thinner, never stop it on your own – call your prescriber first.
An estimated 900,000 Americans are affected by venous thromboembolism (VTE) each year, and deep vein thrombosis accounts for roughly two-thirds of those cases. According to the CDC, deep vein thrombosis – a blood clot that forms in a deep vein, usually in the leg – contributes to as many as 100,000 deaths in the United States each year when clots break loose and travel to the lungs, though exact figures vary by how deaths are counted. Many of these deaths are considered preventable with awareness, early treatment, and appropriate prevention strategies. For an overview of conditions affecting Americans, see our medical conditions guide.
What Is Deep Vein Thrombosis?
Deep vein thrombosis (DVT) occurs when a blood clot (thrombus) forms in one of the deep veins of the body, most commonly in the legs – particularly in the calf, thigh, or pelvic veins. Unlike superficial veins that are visible beneath the skin, deep veins run through the muscles and carry the majority of blood returning from the legs to the heart.
The danger of DVT lies not just in the clot itself but in what can happen if it detaches. When a DVT breaks free and travels through the bloodstream to the lungs, it lodges in a pulmonary artery, blocking blood flow – a condition called pulmonary embolism (PE). PE can be immediately life-threatening. Together, DVT and PE are referred to as venous thromboembolism (VTE), and clinicians think of them as two ends of the same disease rather than two separate problems.
The NHLBI notes that DVT can occur at any age but becomes more common after age 60. It can also affect upper-extremity deep veins – a presentation increasingly seen with the use of central venous catheters and in certain occupational or athletic contexts. Understanding DVT risk factors and symptoms can be lifesaving.
Causes: Virchow’s Triad
The formation of blood clots in deep veins is explained by three interacting factors described in 1856 by the German physician Rudolf Virchow – a framework known as Virchow’s Triad:
1. Venous stasis (slowed blood flow): When blood moves slowly or pools in the veins, clots are more likely to form. This occurs during prolonged immobility – bed rest after surgery, long flights or car rides, extended sitting at a desk, or paralysis. It is also why hospitalization is one of the strongest risk factors for DVT.
2. Endothelial injury (damage to the vein wall): Trauma, surgery (especially orthopedic surgery involving the hip or knee), intravenous catheters, and prior DVT can damage the inner lining of veins, triggering the clotting cascade.
3. Hypercoagulability (increased tendency of blood to clot): Certain conditions make blood more “sticky” – including genetic clotting disorders (Factor V Leiden, prothrombin gene mutation), cancer, pregnancy, estrogen-containing medications (oral contraceptives, hormone replacement therapy), obesity, and systemic inflammatory conditions.
According to the Mayo Clinic, DVT often results from a combination of these factors – for example, a person with a genetic clotting tendency who undergoes surgery and is immobilized during recovery faces a substantially elevated risk. The more risk factors that stack up at the same time, the higher the danger.
Risk Factors
Understanding your personal risk factors is the first step toward prevention. Major risk factors for DVT include:
- Recent surgery – especially hip replacement, knee replacement, and abdominal or pelvic surgery
- Prolonged immobility – hospitalization, bed rest, long-distance travel (flights over about 4 hours), leg casting
- Cancer – both the cancer itself and its treatment (including chemotherapy) increase clotting risk
- Inherited clotting disorders – Factor V Leiden (present in roughly 3-5% of people of European ancestry), prothrombin G20210A mutation, protein C/S deficiency, antithrombin deficiency
- Estrogen – oral contraceptives, hormone replacement therapy, pregnancy, and the postpartum period
- Obesity – a higher body mass index roughly doubles DVT risk
- Age – risk increases steadily after 40, with sharper rises after 60
- Smoking – damages blood vessels and increases hypercoagulability
- Prior DVT/PE – one of the strongest risk factors for recurrence; a substantial share of people will have another VTE within 10 years
- Central venous catheters – a common cause of upper-extremity DVT
Severe COVID-19 infection has also been linked to an increased risk of blood clots, particularly among hospitalized patients, and this elevated risk can persist for a period after the acute illness. Research on the exact magnitude continues to evolve, so if you have had a serious infection and develop leg or breathing symptoms, mention it to your clinician.
Symptoms
Roughly half of DVTs produce noticeable symptoms, while the other half are clinically silent and may only be discovered when a pulmonary embolism occurs. When symptoms are present, they typically include:
Leg swelling – usually in one leg, though bilateral DVT can occur. The swelling may develop gradually over hours or rapidly. Pain or tenderness in the calf or thigh, often described as a cramp or soreness that worsens with standing or walking. Warmth over the affected area. Redness or discoloration – the skin may appear reddish or have a bluish hue. Superficial vein distension – visible engorgement of the superficial veins overlying the clot.
Symptoms of pulmonary embolism – which may be the first indication that a DVT exists – include sudden shortness of breath, sharp chest pain that worsens with deep breathing (pleuritic pain), rapid heartbeat, coughing (sometimes with blood), lightheadedness or fainting, and a sense of impending doom.
Diagnosis
When DVT is suspected, a combination of clinical assessment, blood tests, and imaging guides the diagnosis. The Wells Score is a clinical prediction tool that estimates the probability of DVT based on risk factors and symptoms. It helps determine whether further testing is needed and which tests to order.
The D-dimer blood test measures a protein fragment produced when blood clots break down. A normal D-dimer is helpful for ruling out DVT in people who are already low-risk (it has high sensitivity but low specificity – meaning a normal result makes DVT unlikely, but an elevated result can be caused by many conditions besides DVT, including infection, surgery, and pregnancy). In higher-probability cases, imaging is pursued regardless of the D-dimer result.
Compression ultrasound is the primary imaging test for DVT. It is non-invasive, widely available, and highly accurate for clots in the thigh (femoral and popliteal veins). The hallmark finding is inability to compress the vein with the ultrasound probe – a normal vein collapses easily, but a vein containing a clot resists compression. For pelvic or iliac vein clots that are harder to visualize, CT venography or MR venography may be used. The Cleveland Clinic notes that if PE is suspected concurrently, a CT pulmonary angiography is typically the test of choice.
Treatment: Blood Thinners (Anticoagulation)
Anticoagulation therapy is the cornerstone of DVT treatment. Blood thinners do not dissolve existing clots – the body’s own fibrinolytic system does that over time – but they prevent the clot from growing and dramatically reduce the risk of pulmonary embolism and recurrent DVT. Every part of this treatment is directed by a clinician; the sections below describe the general approach, not a self-treatment plan, and deliberately include no dosing.
Direct oral anticoagulants (DOACs) – such as apixaban (Eliquis) and rivaroxaban (Xarelto) – are the preferred first-line treatment for most DVT cases in current guidelines from bodies like the American Society of Hematology. They are taken orally, do not require routine blood monitoring, have fewer drug and food interactions than warfarin, and in most cases can be started without an initial injectable blood thinner. Edoxaban and dabigatran are alternatives but require a lead-in period with injectable anticoagulation. Lower-cost generic versions of some DOACs, including apixaban, have begun reaching the U.S. market, which may reduce out-of-pocket costs over time – ask your pharmacist about current availability and pricing.
Warfarin remains an option, particularly for people with certain conditions (such as antiphospholipid syndrome) or for cost considerations. It requires regular INR blood monitoring to maintain therapeutic levels and has significant food and drug interactions. When warfarin is used, it is typically overlapped with injectable heparin (either low-molecular-weight heparin such as enoxaparin or intravenous unfractionated heparin) for a period and until the INR is in the target range.
The duration of anticoagulation depends on the circumstances. A DVT provoked by a clear, temporary risk factor (such as surgery or immobilization) is often treated for around three months. An unprovoked DVT, or one associated with ongoing risk factors (cancer, inherited clotting disorders), may call for extended or indefinite anticoagulation. The decision about treatment duration involves balancing recurrence risk against bleeding risk and is made collaboratively between you and your doctor – it is not something to shorten or extend on your own. Understanding healthcare costs is useful when comparing DOAC and warfarin options over the long term. Do not stop a blood thinner because you feel better or because of cost concerns without first talking to your prescriber; stopping early is one of the most common causes of a second, preventable clot.
Other Treatment Approaches
Thrombolysis and Thrombectomy
For extensive DVT – particularly iliofemoral DVT (involving the large veins in the pelvis and upper thigh) with severe symptoms – catheter-directed thrombolysis may be considered. This involves threading a catheter directly into the clot and infusing a clot-dissolving medication over hours. Pharmacomechanical thrombectomy combines thrombolytic medication with mechanical clot removal. These approaches can provide rapid symptom relief and may reduce the risk of post-thrombotic syndrome in selected patients, though they carry a higher bleeding risk than anticoagulation alone and are reserved for specific situations.
IVC Filters
Inferior vena cava (IVC) filters are small devices placed in the large vein that carries blood from the lower body to the heart. They catch clots that break free from leg veins before they can reach the lungs. IVC filters are generally reserved for people who cannot take anticoagulation (due to active bleeding, for example) or who develop PE despite adequate anticoagulation. Retrievable filters should be removed once the contraindication to anticoagulation resolves, as long-term filters carry their own risk of complications.
Compression Therapy
Graduated compression stockings were once routinely prescribed after DVT to prevent post-thrombotic syndrome. However, the SOX trial, published in The Lancet, found that stockings did not reliably prevent post-thrombotic syndrome. Current guidelines therefore do not universally recommend them for that purpose, though they may still provide symptomatic relief for people with leg swelling and discomfort. Your care team can advise whether they are worthwhile in your case.
Long-Term Complications
Post-thrombotic syndrome (PTS) develops in a meaningful share of people who have had a DVT – commonly cited as roughly 20-50% – typically within two years. It occurs when the clot damages the valves inside the vein, causing chronic venous insufficiency: blood pools in the affected leg, leading to persistent swelling, pain, heaviness, skin discoloration, and, in severe cases, chronic leg ulcers. There is no cure for PTS; management focuses on leg elevation, compression therapy, exercise, and wound care when ulcers develop.
Recurrent VTE is a significant concern – the cumulative risk of recurrence over the years after a first unprovoked DVT is substantial. Each recurrence further damages the venous system and increases the risk of PTS. This is why extended anticoagulation is considered for unprovoked DVT.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious complication of PE. Unresolved clot material in the pulmonary arteries causes chronic obstruction, leading to progressive right heart failure. CTEPH is treatable with surgical pulmonary endarterectomy or balloon pulmonary angioplasty, but early recognition is essential. According to the NHLBI, persistent, unexplained shortness of breath after a PE should prompt evaluation for CTEPH.
Prevention
DVT prevention is critical, particularly in high-risk situations. After surgery: early mobilization, mechanical compression devices (sequential compression devices on the legs), and prophylactic blood thinners are standard protocols for many surgical patients. During hospitalization: risk assessment using tools like the Padua or Caprini scores helps determine which medical patients should receive DVT prophylaxis.
During travel: for flights or car rides longer than about four hours, get up and walk periodically, perform seated calf exercises (ankle circles, foot pumps), stay hydrated, and avoid excess alcohol and sedatives. Compression stockings can provide additional protection for those at elevated risk. Routine aspirin is not recommended for travel-related DVT prevention in the general population; if you are at high risk, ask your clinician what is appropriate for you.
Lifestyle factors: maintaining a healthy weight, staying physically active, quitting smoking, and avoiding prolonged sitting (taking breaks to stand and walk every 1-2 hours) all reduce baseline DVT risk. If you take estrogen-containing medications, discuss the thrombotic risk with your doctor – particularly if you have other risk factors.
DVT at a Glance
| Aspect | Key points |
|---|---|
| Where it forms | Deep veins, most often the calf, thigh, or pelvis; sometimes the arm |
| Warning signs | One-sided leg swelling, pain/tenderness, warmth, redness |
| Emergency (PE) | Sudden breathlessness, chest pain with breathing, coughing blood, fainting – call 911 |
| Diagnosis | Wells score, D-dimer, compression ultrasound (CT for PE) |
| Main treatment | Anticoagulation (DOACs often first-line), clinician-directed, no self-dosing |
| Long-term risks | Post-thrombotic syndrome, recurrent clots, rarely CTEPH |
Frequently Asked Questions
How serious is a deep vein thrombosis?
DVT is a serious medical condition that requires prompt treatment. The primary acute danger is pulmonary embolism, which can be fatal. With appropriate anticoagulation started promptly, the risk of PE drops dramatically. Long-term complications include post-thrombotic syndrome and recurrent clots. DVT should never be ignored or treated with “wait and see” – seek medical attention the same day you notice symptoms.
Can DVT go away on its own?
The body’s natural fibrinolytic system can eventually dissolve a clot, but waiting for that to happen without treatment is dangerous – the clot can grow, cause PE, or permanently damage the vein valves. Anticoagulation is needed to prevent clot extension and embolization while the body dissolves the existing clot. Many DVTs resolve substantially within three to six months of anticoagulation, though some residual clot may persist.
Can you fly with DVT?
If you have an acute DVT, air travel is generally not recommended until you have been on anticoagulation and your symptoms are improving; the exact timing is a decision for your clinician. The combination of immobility and cabin conditions during flight can worsen the situation. Once you are on stable anticoagulation and your symptoms have improved, air travel is generally considered safe with appropriate precautions – staying hydrated, wearing compression stockings if advised, and walking regularly during the flight.
Is DVT hereditary?
Genetic factors play a significant role in DVT risk. Inherited clotting disorders – particularly Factor V Leiden and the prothrombin gene mutation – are present in a small percentage of the general population and increase DVT risk. If you have a first-degree relative who had an unprovoked DVT, especially before age 50, thrombophilia testing may be appropriate. However, having a genetic clotting disorder does not guarantee you will develop DVT – it raises your risk, particularly when combined with other factors.
How long do you take blood thinners for DVT?
For a DVT caused by a temporary, identifiable risk factor (surgery, immobility, travel), around three months of anticoagulation is common. For an unprovoked DVT, at least three months are typical, with consideration of longer-term treatment based on your individual recurrence and bleeding risk. For DVT associated with active cancer, anticoagulation often continues as long as the cancer is present and being treated. The decision is individualized – discuss the risks and benefits with your hematologist or vascular medicine specialist, and do not stop early on your own.
Can I take aspirin instead of a prescription blood thinner?
No. Aspirin is not an adequate substitute for anticoagulation in treating an acute DVT. It is a much weaker antithrombotic and does not provide the same protection against clot growth or embolization. In some situations a clinician may consider low-dose aspirin as part of an extended prevention strategy after the initial treatment course, but that is a decision for your doctor – not a swap you should make yourself.
What to Do If You Suspect DVT
If you notice new, unexplained swelling, pain, or redness in one leg – particularly if you have risk factors – do not wait. Contact your doctor the same day or go to an urgent care facility or emergency room where an ultrasound can be performed. Early diagnosis and treatment prevent the potentially fatal complication of pulmonary embolism and reduce the risk of long-term vein damage.
If you have already been treated for DVT, stay vigilant. Take your blood thinners exactly as prescribed – missing doses significantly increases your risk of recurrence. Attend follow-up appointments. Know the symptoms of PE and seek emergency care instantly if they occur. And if your doctor recommends extended anticoagulation, understand that the recommendation is based on your individual risk profile – the inconvenience of daily medication is a small price compared with the consequences of another clot.
This article is general education, not medical advice, and is not a substitute for care from a qualified clinician. It does not include drug dosing on purpose: the choice of anticoagulant and how long to take it must be individualized by your prescriber. Do not start, stop, or change any blood thinner on your own. If you may have a pulmonary embolism, call 911.
Sources
- CDC (Centers for Disease Control and Prevention), Venous Thromboembolism (Blood Clots) – cdc.gov/blood-clots
- NHLBI (National Heart, Lung, and Blood Institute), Venous Thromboembolism – nhlbi.nih.gov
- MedlinePlus (U.S. National Library of Medicine), Deep Vein Thrombosis – medlineplus.gov
- Mayo Clinic, Deep Vein Thrombosis (DVT) – mayoclinic.org
- American Society of Hematology (ASH), Venous Thromboembolism Guidelines – hematology.org